Skip to main content
. 2019 Aug 11;11(8):405. doi: 10.3390/pharmaceutics11080405

Scheme 1.

Scheme 1

The general strategy of conducted studies: (a) double emulsion (w/o/w) design for co-encapsulation of Verteporfin (VP) and Cisplatin (CisPt) in various Poly(Lactide-co-Glycolide) (PLGA) nanocarriers (NCs) and (b) electroporation (EP)-supported photodynamic therapy (PDT) using obtained NCs against human ovarian cancer (SKOV-3) and hamster ovarian control (CHO-K1) cells.